TUCSON, Ariz., (January 3, 2017)—Health care M+A advisory firm Vertess continues its global market expansion with the addition of Teresa Gonzalo, a pharmaceutical and biotechnology entrepreneur with extensive experience in the European market, as a managing director.
Teresa has co-authored two patents in nanotechnology and drug delivery and was awarded the 2011 MIT TR35 Innovator of the Year award by the Massachusetts Institute of Technology. She was also selected as Woman of the Year by the magazine Scientific Entrepreneurial Woman Today.
Teresa received her MBA from IE business school and a PhD in nanomedicine from Groningen University in Holland. She was the CEO and co-founder of Ambiox Biotech and head of the United States’ office for Venture Valuation, where she evaluated health care companies facing a fundraising event, licensing deals or an M+A transaction.
In addition to her PharmD, PhD and MBA credentials, Teresa recently received her Certified Merger and Acquisition Advisor (CMAA) certification through the international Alliance of Merger and Acquisitions Advisors (AMAA).
"I am very excited to join the Vertess team and hope my strong entrepreneurial background, especially within the Pharma and Biotech sectors, will help us to expand," Teresa remarked. "This position allows me to feed my curiosity about the latest innovations and technology while participating in exciting transactions in the healthcare sector. There are many new encouraging developments in the pharma, medtech and diagnostics verticals and I foresee strong growth in 2017 and beyond."
Tom Schramski, Vertess Managing Partner, said, "Teresa is a leader in her field and she brings this expertise to her role as a managing director at Vertess. She will help us provide our advisory services to a growing, dynamic life sciences marketplace."
Visit vertess.com for more information.
